Biosimilars in oncology.

Authors

  • Sérgio Barroso Hospital do Espírito Santo, Evora.
  • Jorge Coutinho
  • Margarida Damasceno
  • José Dinis
  • João Forjaz de Lacerda
  • Helena Gervásio
  • Fernando Leal da Costa
  • Ana Marques Pereira
  • António Parreira
  • Fernando Principe
  • Helena Rodrigues
  • Anabela Sá
  • Adriana Teixeira

DOI:

https://doi.org/10.20344/amp.1706

Abstract

The development of biotechnology drugs represents one of the great advances in medical therapy and it was observed an exponential growth in its use. The resource to these drugs in Oncology and Hematology is no exception and it soon became an essential element of an integrated and directed therapy strategy. The expiry of the first biotechnology drugs patents has opened the door for the development and marketing of biosimilars, which entry in the Portuguese market was recently approved. This article was built on the analysis of the available state-of-the-art information on biotechnology drugs, biosimilars and current legislation and it expresses the opinion of Oncology and Hematology experts about the substituition of biological drugs by biosimilars in clinical practice.

Downloads

Download data is not yet available.

Downloads

How to Cite

1.
Barroso S, Coutinho J, Damasceno M, Dinis J, Forjaz de Lacerda J, Gervásio H, Leal da Costa F, Marques Pereira A, Parreira A, Principe F, Rodrigues H, Sá A, Teixeira A. Biosimilars in oncology. Acta Med Port [Internet]. 2009 Jun. 30 [cited 2024 Dec. 23];22(3):203-6. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/1706

Issue

Vol. 22 No. 3 (2009): Maio-Junho

Section

Arquivo Histórico

License

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.

Crossref
Scopus
Google Scholar
Europe PMC